Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
=====================================================================================================================================================================================================

* Robert HI Andtbacka
* Frances A Collichio
* Thomas Amatruda
* Neil Senzer
* Jason Chesney
* Keith Delman
* Lynn Spitler
* Igor Puzanov
* Sanjiv Agarwala
* Mohammed Milhem
* Kevin Harrington
* Mark Middleton
* Ai Li
* Mark Shilkrut
* Robert Coffin
* Howard Kaufman